StockNews.com Initiates Coverage on Cutera (NASDAQ:CUTR)

Research analysts at StockNews.com started coverage on shares of Cutera (NASDAQ:CUTR) in a research note issued on Sunday. The brokerage set a “sell” rating on the medical device company’s stock.

Cutera Stock Up 28.1 %

NASDAQ CUTR opened at $0.62 on Friday. Cutera has a twelve month low of $0.28 and a twelve month high of $4.97. The business has a 50-day moving average price of $0.41 and a 200-day moving average price of $0.79. The firm has a market cap of $12.51 million, a price-to-earnings ratio of -0.09 and a beta of 1.31.

Institutional Investors Weigh In On Cutera

A number of institutional investors have recently added to or reduced their stakes in the stock. Ground Swell Capital LLC bought a new position in shares of Cutera during the second quarter worth $37,000. Bank of Montreal Can lifted its stake in Cutera by 14.2% in the 2nd quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock worth $455,000 after purchasing an additional 35,248 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in shares of Cutera by 164.5% during the 2nd quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after purchasing an additional 70,870 shares during the last quarter. 90.70% of the stock is owned by hedge funds and other institutional investors.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.